The US dollar extends its rally against the Japanese yen, advancing for the third consecutive day, trading at 114.36 during the New York session at press time. Positive news on the Covid-19 Omicron-variant front is cheered by investors as the Santa Rally finally kicked in. European equity indices rise between 0.93% and 1.42%, while US stock indices advance between 0.62% and 0.70%.
The US Food and Drug Administration (FDA) has authorized Covid-19 treatments in the last two days. On Wednesday, it approved Pfizer’s Plaxovid, treatment for high-risk patients. By Thursday, Molnupravir, a treatment pill developed by Merck, received the green light from the FDA. Both treatments would help to curb rising infections from overwhelming hospitals.
US T-bond yields rallied on the news, with the 10-year US Treasury yield rising three basis points, closing at 1.50%, and underpining the USD/JPY. In the meantime, the US Dollar Index, which tracks the buck’s performance against a basket of six rivals, is barely up 0.03%, at 96.10.
The USD/JPY daily chart depicts the pair has having an upside bias, supported by the daily moving averages (DMAs) residing below the spot price. Additionally, an upslope trendline drawn from the September swing lows towards the late November lows stalled sell-offs moves three times.
To the upside, the USD/JPY's first line of resistance would be the October 20 cycle high at 114.70. A breach of the latter could pave the way for further USD/JPY gains. The next resistance would be the psychological 115.00 figure, followed by the November 24 cycle high and YTD high at 115.52.
On the flip side, the USD/JPY's first demand zone would be the 50-DMA at 113.87. A break beneath that support would open the door for a test of the upsloping trendline around the 113.60-75 range, followed by the December 17 pivot low at 113.14.
Risk Warning: Trading Forex and CFDs on margin carries a high level of risk and may not be suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 72.72% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Prior to trading, you should take into consideration your level of experience and financial situation. TeleTrade strives to provide you with all the necessary information and protective measures, but, if the risks seem still unclear to you, please seek independent advice.
© 2011-2022 Teletrade-DJ International Consulting Ltd
Teletrade-DJ International Consulting Ltd is registered as a Cyprus Investment Firm (CIF) under registration number HE272810 and is licensed by the Cyprus Securities and Exchange Commission (CySEC) under license number 158/11.
The company operates in accordance with the Markets in Financial Instruments Directive (MiFID).
The content on this website is for information purposes only. All the services and information provided have been obtained from sources deemed to be reliable. Teletrade-DJ International Consulting Ltd ("TeleTrade") and/or any third-party information providers provide the services and information without warranty of any kind. By using this information and services you agree that under no circumstances shall TeleTrade have any liability to any person or entity for any loss or damage in whole or part caused by reliance on such information and services.
TeleTrade cooperates exclusively with regulated financial institutions for the safekeeping of clients' funds. Please see the entire list of banks and payment service providers entrusted with the handling of clients' funds.
Teletrade-DJ International Consulting Ltd currently provides its services on a cross-border basis, within EEA states (except Belgium) under the MiFID passporting regime, and in selected 3rd countries. TeleTrade does not provide its services to residents or nationals of the USA.